Alnylam napoveduje predhodne* globalne neto prihodke od izdelkov za četrto četrtletje in celotno leto 2022 in ponuja dodatne posodobitve

– Achieved Full Year 2022 Preliminary Global Net Product Revenues of $894 Million for ONPATTRO^®, AMVUTTRA^®, GIVLAARI^®in OXLUMO^®, kar predstavlja 35 % letno rast (43 % ob uporabi stalnega menjalnega tečaja**) –

– Strength of AMVUTTRA Launch Drove 37% Total TTR Annual Revenue Growth –

– Ohranjena močna bilanca stanja s stanjem denarja in naložb ob koncu leta v višini približno 2.2 milijarde USD –

CAMBRIDGE, Massachusetts - (POSLOVNA ŽICA) -Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), vodilno terapevtsko podjetje RNAi, je danes objavilo svoje predhodne* četrto četrtletje in celotno leto 2022 globalne neto prihodke od izdelkov za ONPATTRO, AMVUTTRA, GIVLAARI in OXLUMO ter zagotovilo dodatne posodobitve komercialnih lansiranj izdelkov.

Predhodna poslovna in finančna uspešnost v četrtem četrtletju in celotnem letu 2022*

Skupni TTR: ONPATTRO^® (patisiran) & AMVUTTRA^® (vutrisiran)

• Predhodni globalni neto prihodki izdelkov za ONPATTRO in AMVUTTRA za četrto četrtletje so znašali približno 122 milijonov USD oziroma 69 milijonov USD, kar predstavlja 12-odstotno skupno četrtletno rast TTR v primerjavi s tretjim četrtletjem 3, za celotno leto 2022 pa približno 2022 milijonov USD oziroma 558 milijonov USD , kar predstavlja 94-odstotno skupno letno rast TTR v primerjavi s celotnim letom 37.
• Do konca leta 2022 je več kot 2,975 bolnikov po vsem svetu prejemalo komercialni ONPATTRO ali AMVUTTRA.

GIVLAARI^® (givosiran)

• Predhodni svetovni neto prihodki od izdelkov za četrto četrtletje in celotno leto 2022 so znašali približno 47 milijonov USD oziroma 173 milijonov USD, kar predstavlja četrtletno in letno rast za 3 % oziroma 35 % v primerjavi s tretjim četrtletjem 3 oziroma celotnim letom 2022.
• Od konca leta 2022 je več kot 520 bolnikov po vsem svetu prejemalo komercialni GIVLAARI.

OXLUMO^® (lumasiran)

• Predhodni svetovni neto prihodki od izdelkov za četrto četrtletje in celotno leto 2022 so znašali približno 24 milijonov USD oziroma 70 milijonov USD, kar predstavlja četrtletno in letno rast za 45 % oziroma 17 % v primerjavi s tretjim četrtletjem 3 oziroma celotnim letom 2022.
• Konec leta 2022 je komercialno zdravilo OXLUMO prejemalo več kot 280 bolnikov po vsem svetu.

Poleg tega je imel Alnylam 31. decembra 2022 predhodno denar, denarne ustreznike in tržne vrednostne papirje v višini približno 2.2 milijarde USD v primerjavi z 2.4 milijarde USD 31. decembra 2021.

“We are pleased to have closed out 2022 on a very strong note with continued execution across our commercial portfolio, delivering top-line revenue in line with our guidance range. These preliminary results reflect healthy patient demand for our transformative products and strong commercial execution by our teams in delivering these important medicines to patients in need around the world. In 2022 we were particularly excited to celebrate the approval and global launch of AMVUTTRA, which has demonstrated an impressive commercial performance in its first two full quarters of launch,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. “As we consider our commercial and financial performance, combined with robust execution on the R&D front, we believe we are well on our way to achieving our Alnylam P⁵x25 cilje, ki postavljajo Alnylam kot vrhunsko, globalno komercialno podjetje z več izdelki s širokim naborom in organsko platformo, ki je pripravljena zagotoviti trajnostne inovacije tudi v prihodnosti, kar je profil, ki ga v naši industriji redko vidimo.«

Vodstvo Alnylama bo razpravljalo o teh predhodno izbranih finančnih rezultatih in komercialnih posodobitvah med predstavitvijo spletnega prenosa na 41.^st Letna konferenca J. P. Morgan Healthcare v San Franciscu v Kaliforniji bo jutri, v ponedeljek, 9. januarja 2023, ob 9 po pacifiškem času (45 po srednjeevropskem času).

O RNAi Therapeutics

RNAi (interferenca RNA) je naravni celični proces utišanja genov, ki predstavlja eno najbolj obetavnih in hitro napredujočih meja v današnji biologiji in razvoju zdravil. Njegovo odkritje je bilo razglašeno za "velik znanstveni preboj, ki se zgodi enkrat na desetletje" in je bilo leta 2006 priznano z Nobelovo nagrado za fiziologijo in medicino. Z izkoriščanjem naravnega biološkega procesa RNAi, ki se pojavlja v naših celicah, je nov razred zdravil, znan kot terapevtik RNAi, zdaj resničnost. Mala interferenčna RNA (siRNA), molekule, ki posredujejo RNAi in sestavljajo Alnylamovo terapevtsko platformo RNAi, delujejo pred današnjimi zdravili tako, da močno utišajo messenger RNA (mRNA) – genetske prekurzorje –, ki kodirajo beljakovine, ki povzročajo bolezni ali bolezni, in tako preprečujejo jih narediti. To je revolucionaren pristop, ki lahko spremeni oskrbo bolnikov z genetskimi in drugimi boleznimi.

O Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi revolucija in še naprej uresničuje drzno vizijo, da znanstveno možnost spremeni v resničnost. Alnylamovi komercialni terapevtski izdelki RNAi so ONPATTRO^® (patisiran), AMVUTTRA^® (vutrisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran) in Leqvio^® (inclisiran), ki ga razvija in komercializira Alnylamov partner Novartis. Alnylam ima bogato ponudbo zdravil v preskušanju, vključno s številnimi možnimi izdelki, ki so v pozni fazi razvoja. Alnylam izvaja na svojem "Alnylam P⁵x25” strategija za zagotavljanje transformativnih zdravil tako za redke kot pogoste bolezni, ki bodo koristila bolnikom po vsem svetu s trajnostnimi inovacijami in izjemno finančno uspešnostjo, kar ima za posledico vodilni biotehnološki profil. Alnylam ima sedež v Cambridgeu, MA. Za več informacij o naših ljudeh, znanosti in plinovodu obiščite www.alnylam.com in sodelujte z nami na Twitterju na @Alnylam, Na LinkedInali naprej Instagram.

Alnylamove izjave o prihodnosti

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, expectations regarding Alnylam’s aspiration to become a leading biotech company and the planned achievement of its "Alnylam P⁵x25” strategy, the potential for Alnylam to identify new potential drug development candidates and advance its research and development programs, Alnylam’s ability to obtain approval for new commercial products or additional indications for its existing products, and Alnylam’s projected commercial and financial performance should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam’s business, results of operations and financial condition and the effectiveness or timeliness of Alnylam’s efforts to mitigate the impact of the pandemic; the potential impact of the January 2022 leadership transition on Alnylam’s ability to attract and retain talent and to successfully execute on its "Alnylam P⁵x25” strategy; the finalization and audit of Alnylam’s fourth quarter and 2022 fiscal year financial results which could potentially result in changes or adjustments to the selected preliminary financial results presented herein; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for its product candidates; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling its approved products globally; delays, interruptions or failures in the manufacture and supply of its product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to successfully expand the indication for ONPATTRO or AMVUTTRA in the future; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products, including Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the potential impact of a current government investigation and the risk of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in its other SEC filings. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

Uporaba finančnih ukrepov, ki niso GAAP

This press release contains a non-GAAP financial measure of Constant Exchange Rate (CER). This measure is not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies. Percentage changes in revenue growth at CER are presented excluding the impact of changes in foreign currency exchange rates for investors to understand the underlying business performance. The current period’s foreign currency revenue values are converted into U.S. dollars using the exchange rates from the prior period. The difference between the reported 35% annual GAAP growth rate and 43% annual CER growth rate is due to the inclusion of 8% additional net product revenue growth in the CER growth rate had exchange rates remained unchanged from 2021.

____________________________

* Predhodni izbrani finančni rezultati so nerevidirani, predmet prilagoditve in so navedeni kot približek pred objavo popolnih finančnih rezultatov družbe februarja 2023.

** CER = stalni menjalni tečaj, ki predstavlja rast, izračunano, kot da bi menjalni tečaji ostali nespremenjeni od tistih, ki so bili uporabljeni v letu 2021. CER je finančna mera, ki ni v skladu z GAAP.

 

Kontakti

Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom

(Vlagatelji in mediji)

617-682-4340

Josh Brodsky

(Vlagatelji)

617-551-8276

• Distribucija vsebine in PR s pomočjo SEO. Okrepite se še danes.
• Platoblockchain. Web3 Metaverse Intelligence. Razširjeno znanje. Dostopite tukaj.
• vir: https://www.fintechnews.org/alnylam-announces-preliminary-fourth-quarter-and-full-year-2022-global-net-product-revenues-and-provides-additional-updates/